文献速递神经肌肉病

夏科-马里-图思病功能结局测量的多中心验证

Multicenter Validation of the Charcot-Marie-Tooth Functional Outcome Measure.
PubMed 文献 · Neurology · 2024-01-18

研究在美国、英国和意大利的夏科-马里-图思病门诊招募214例18-75岁CMT1A成人,通过项目分析、因子分析和Rasch模型等验证12条目CMT-FOM。结果显示该量表为单维度区间量表,覆盖力量、上下肢功能、平衡和 mobility,评分0-100分,模型拟合良好。

要点

  • CMT-FOM为12条目单维度量表,覆盖力量、上下肢功能、平衡和移动能力。
  • CMT-FOM与CMT检查评分(r=0.643;p<0.001)和总体神经病变限制量表(r=0.516;p<0.001)显著相关。
  • 自报每日出行跌倒、踝关节不稳、手震颤和手无力的参与者CMT-FOM总分显著更高(p<0.05)。

核心结论

  • CMT-FOM是一种心理测量学稳健的多条目、单维度、疾病特异性临床结局评估工具,用于捕捉CMT1A参与者的功能状态以识别治疗疗效。

研究设计与样本

  • 通过美国(n=130)、英国(n=52)和意大利(n=32)的CMT门诊招募参与者,共纳入214例18-75岁CMT1A患者(58%女性)。
  • 开展了一系列验证研究,包括项目分析和因子分析、Rasch模型分析以及评分者间信度、区分能力和收敛效度测试。

主要发现

  • 项目、因子和Rasch分析支持12条目CMT-FOM作为CMT1A成人功能单维度区间量表的可行性。
  • 0-100分评分系统显示良好的整体模型拟合,无失拟条目证据,无个体失拟,且对CMT1A成人靶向良好。
  • CMT-FOM与CMT检查评分显著相关(r=0.643;p<0.001),与总体神经病变限制量表显著相关(r=0.516;p<0.001)。
  • 自报每日出行跌倒、踝关节不稳、手震颤和手无力的参与者CMT-FOM总分显著更高(p<0.05)。

关键数值与推荐

  • CMT-FOM为12条目、0-100分评分系统,覆盖力量、上下肢功能、平衡和移动能力。
  • 与CMT检查评分的相关系数r=0.643(p<0.001),与总体神经病变限制量表的相关系数r=0.516(p<0.001)。
  • 自报每日出行跌倒、踝关节不稳、手震颤和手无力者的CMT-FOM总分显著更高(p<0.05)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Charcot-Marie-Tooth disease type 1A (CMT1A), caused by a duplication of PMP22, is the most common hereditary peripheral neuropathy. For participants with CMT1A, few clinical trials have been performed; however, multiple therapies have reached an advanced stage of preclinical development. In preparation for imminent clinical trials in participants with CMT1A, we have produced a Clinical Outcome Assessment (COA), known as the CMT-Functional Outcome Measure (CMT-FOM), in accordance with the FDA Roadmap to Patient-Focused Outcome Measurement to capture the key clinical end point of function. METHODS: Participants were recruited through CMT clinics in the United States (n = 130), the United Kingdom (n = 52), and Italy (n = 32). To derive the most accurate signal with the fewest items to identify a therapeutic response, a series of validation studies were conducted including item and factor analysis, Rasch model analysis and testing of interrater reliability, discriminative ability, and convergent validity. RESULTS: A total of 214 participants aged 18-75 years with CMT1A (58% female) were included in this study. Item, factor, and Rasch analysis supported the viability of the 12-item CMT-FOM as a unidimensional interval scale of function in adults with CMT1A. The CMT-FOM covers strength, upper and lower limb function, balance, and mobility. The 0-100 point scoring system showed good overall model fit, no evidence of misfitting items, and no person misfit, and it was well targeted for adults with CMT1A exhibiting high inter-rater reliability across a range of clinical settings and evaluators. The CMT-FOM was significantly correlated with the CMT Examination Score (r = 0.643; p < 0.001) and the Overall Neuropathy Limitation Scale (r = 0.516; p < 0.001). Significantly higher CMT-FOM total scores were observed in participants self-reporting daily trips and falls, unsteady ankles, hand tremor, and hand weakness (p < 0.05). DISCUSSION: The CMT-FOM is a psychometrically robust multi-item, unidimensional, disease-specific COA covering strength, upper and lower limb function, balance, and mobility to capture how participants with CMT1A function to identify therapeutic efficacy.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Mandarakas MR, Eichinger KJ, Bray P, et al. Multicenter Validation of the Charcot-Marie-Tooth Functional Outcome Measure. Neurology. 2024. PMID: 38237108. doi:10.1212/WNL.0000000000207963

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。